0QAV.LSE Nanobiotix

Healthcare Oil, Gas & Consumable Fuels London Exchange
31.32 EUR
Close of Oct 12, 2026
16.52 47.60
Market cap
EUR 614M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0QAV.LSE undervalued?

Graham number

The Graham number of Nanobiotix cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nanobiotix fundamental analysis

No fundamental analysis for Nanobiotix yet.

Nanobiotix stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nanobiotix

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to de…

Full company profile